Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EPS (Weighted Average and Diluted) (2020 - 2025)

Lyell Immunopharma's EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$2.13 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 38.79% year-over-year to -$2.13; the TTM value through Sep 2025 reached $0.8, up 110.65%, while the annual FY2024 figure was -$1.31, 40.86% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$2.13 at Lyell Immunopharma, up from -$2.89 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $6.0 in Q4 2024 and bottomed at -$3.59 in Q2 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.25 (2023), against an average of -$0.53.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 3100.0% in 2024 against a maximum downside of 1640.0% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.18 in 2021, then skyrocketed by 83.33% to -$0.03 in 2022, then crashed by 566.67% to -$0.2 in 2023, then skyrocketed by 3100.0% to $6.0 in 2024, then plummeted by 135.5% to -$2.13 in 2025.
  • Per Business Quant, the three most recent readings for LYEL's EPS (Weighted Average and Diluted) are -$2.13 (Q3 2025), -$2.89 (Q2 2025), and -$0.18 (Q1 2025).